Clinical trial
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B…
NCT00076336 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00076336 |
|---|---|
| Title | Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis |
| Official title | Randomized, Double-Blind Trial of Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis, Hepatitis B, Chronic, Cirrhosis |
| Intervention type | Drug |
| Interventions | Telbivudine, Lamivudine, Placebo |
| Enrollment | 232 |
| Start date | Dec 1, 2003 |
| Primary completion | Dec 1, 2009 |
| First posted | Jan 22, 2004 |
| Last update posted | Sep 5, 2011 |
| Countries | Australia, Canada, China, France, Germany, India, Israel, Latvia, Malaysia, New Zealand, Poland, Russia and 9 more |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: